Pengpeng Xu - Shanghai Institute of Hematology, Shanghai Jiao Tong University

基本信息

浏览量：31

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 137 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Dual Targeting PD-L1 and 4-1BB to Overcome Dendritic Cell-Mediated Lenalidomide Resistance in Follicular Lymphoma

Zhong Zheng, Jian-Biao Wang,Rui Sun,Nan Wang,Xiang-Qin Weng, Tian-Yuan Xu,Di Fu,Yan Feng,Peng-Peng Xu,Shu Cheng,Li Wang,Yan Zhao,Bin Qu,Chuan-Xin Huang,Wei-Li Zhao

Signal Transduction and Targeted Therapyno. 1 (2025): 1-13

引用0浏览0WOSNATURE引用

Targeted Agents Plus CHOP Compared with CHOP As the First-Line Treatment for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma (GUIDANCE-03): an Open-Label, Multicentre Phase 2 Clinical Trial

Ming-Ci Cai,Shu Cheng,Hong-Mei Jing,Yan Liu,Guo-Hui Cui,Ting Niu,Jian-Zhen Shen,Liang Huang,Xin Wang,Yao-Hui Huang,Li Wang,Peng-Peng Xu,Wei-Li Zhao

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2024)

引用0浏览0WOS引用

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Siyuan Chen,Li Wang,Pengpeng Xu,Shu Cheng,Wei Tang, Wen Wu,Mengmeng Ji,Zhong Zheng,Zixun Yan,Lingshuang Sheng,Yige Shen,Weili Zhao

Bloodno. Supplement 1 (2024): 6553-6553

引用0浏览0引用

Effect of Therapeutic Erythrocytapheresis on Outcomes and Renal Benefit in Patients with High-Altitude Polycythemia: a Real-World Study

Yan Ouyang, Yinyin Zhang, Huan Li,Luo Bu Zhuo Ma, Ci Ren De Ji, Chunyan Qiao,Ba Dun,Xiaodong Gao, Jun Zhu,Pengpeng Xu,Yu Zheng, Xiaoyang Li,Jianhua You,Chuanhe Jiang,Fei Yue,Junmin Li, Pu Bu Wang Dui,Kai Xue,Kai Qing

SCIENTIFIC REPORTSno. 1 (2024)

引用0浏览0WOSNATURE引用

Anti-metabolic Agent Pegaspargase Plus PD-1 Antibody Sintilimab for First-Line Treatment in Advanced Natural Killer T Cell Lymphoma

Jie Xiong,Shu Cheng, Xiao Gao,Shan-He Yu,Yu-Ting Dai,Xin-Yun Huang,Hui-Juan Zhong,Chao-Fu Wang,Hong-Mei Yi, Hao Zhang,Wei-Guo Cao,Rong Li,Wei Tang,Yan Zhao,Peng-Peng Xu,Li Wang,Wei-Li Zhao

Signal Transduction and Targeted Therapyno. 1 (2024)

引用1浏览0WOSNATURE引用

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Lingshuang Sheng,Zixun Yan,Li Wang, Wen Wu,Yilun Zhang,Rong Shen,Weiguo Cao, Lei Li,Sheng Chen,Xufeng Jiang,Hongmei Yi,Qi Song,Shu Cheng,Pengpeng Xu,Xuanming Yang, Yuxiang Zhu, Xikang Xu, Fuzhe Wang,Jianyong Li,Wei Li Zhao

Bloodno. Supplement 1 (2024): 4822-4822

引用0浏览0引用

18F-FDG PET/CT Metrics-Based Stratification of Large B-cell Lymphoma Receiving CAR-T Cell Therapy: Immunosuppressive Tumor Microenvironment As a Negative Prognostic Indicator in Patients with High Tumor Burden

Ling-Shuang Sheng,Rong Shen,Zi-Xun Yan, Chao Wang, Xin Zheng,Yi-Lun Zhang, Hao-Xu Yang,Wen Wu,Peng-Peng Xu,Shu Cheng,Emmanuel Bachy,Pierre Sesques,Nicolas Jacquet-Francillon,Xu-Feng Jiang,Wei-Li Zhao,Li Wang

Biomarker researchno. 1 (2024): 104-104

引用0浏览0WOS引用

肾脏累及的弥漫性大B细胞淋巴瘤患者临床病理特征

王博恩, 陈思远,施晴,张慕晨,易红梅,董磊, 王黎,程澍,许彭鹏,赵维莅

doaj（2024）

引用0浏览0引用

Tucidinostat Plus R-CHOP in Previously Untreated Diffuse Large B-cell Lymphoma with Double Expression of MYC and BCL2: an Interim Analysis from the Phase III DEB Study

JOURNAL OF CLINICAL ONCOLOGYno. 17_SUPPL (2024): LBA7003-LBA7003

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn